111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
奥洛他定对全身麻醉期间舒芬太尼所致咳嗽的影响：一项前瞻性随机对照临床研究
Authors Gong WY, Li CG, Ge CL, Zhao CX, Yuan W, Yue XF, Fan K
Received 19 May 2025
Accepted for publication 21 November 2025
Published 17 December 2025 Volume 2025:19 Pages 11317—11324
DOI https://doi.org/10.2147/DDDT.S541146
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Georgios Panos
Wen-Yi Gong,1,* Chen-Guang Li,2,* Chun-Lin Ge,1,* Chun-Xia Zhao,3 Wei Yuan,1 Xiao-Fang Yue,4 Kun Fan5
1Department of Anesthesiology, Shanghai Xuhui Central Hospital, Shanghai, People’s Republic of China; 2Department of Anesthesiology, The First People’s Hospital of Tianshui, Gansu, People’s Republic of China; 3Department of Medical Education and Research, The First People’s Hospital of Tianshui, Gansu, People’s Republic of China; 4Department of Neurology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 5Department of Anesthesiology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Kun Fan, Department of Anesthesiology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, No. 600, Yishan Road, Shanghai, 200233, People’s Republic of China, Tel +8618964917372, Fax +8602164701361, Email fankunmazui@hotmail.com Xiao-Fang Yue, Department of Neurology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiaotong University, No. 600, Yishan Road, Shanghai, 200233, People’s Republic of China, Tel +8615821237895, Fax +8602164701361, Email klyxf@126.com
Background: Sufentanil-induced cough (SIC) frequently occurs during the induction of general anesthesia and may result in serious clinical complications, occasionally posing life-threatening risks. In clinical practice, we observed that oliceridine—a G protein-biased μ-opioid receptor agonist—demonstrates a potent suppressive effect on SIC. This study aimed to evaluate the efficacy of oliceridine in preventing SIC and to assess any associated adverse events.
Methods: In this prospective, randomized, double-blind, placebo-controlled trial, 286 adult patients undergoing elective surgery under general anesthesia were enrolled and randomly assigned to receive either 2 mg oliceridine (OS group) or an equal volume of normal saline (SS group) before intravenous administration of sufentanil. The primary outcome was the incidence of SIC. Secondary outcomes included the severity of cough, vital sign changes, and adverse events.
Results: The incidence of SIC was 42.66% in the SS group and 0% in the OS group (95% upper confidence bound ≈ 2.6%; P < 0.001). Among the SS group, mild, moderate, and severe cough occurred in 12.59%, 26.57%, and 3.50% of patients, respectively. No significant differences were observed in systolic or diastolic blood pressure, heart rate, or SpO2 between the two groups at baseline or 2 minutes post-sufentanil administration. The incidence of adverse events was low and comparable between groups, with no reported cases of apnea, nausea, or vomiting.
Conclusion: Pretreatment with 2 mg oliceridine demonstrated favorable effevtiveness in suppressing SIC without significant adverse effects. Oliceridine appears to be a safe and effective prophylactic strategy for preventing SIC and may have valuable clinical utility in anesthesia practice.
Keywords: oliceridine, sufentanil, opioid-induced cough, general anesthesia, μ-opioid receptor
1Department of Anesthesiology, Shanghai Xuhui Central Hospital, Shanghai, People’s Republic of China; 2Department of Anesthesiology, The First People’s Hospital of Tianshui, Gansu, People’s Republic of China; 3Department of Medical Education and Research, The First People’s Hospital of Tianshui, Gansu, People’s Republic of China; 4Department of Neurology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 5Department of Anesthesiology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Kun Fan, Department of Anesthesiology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, No. 600, Yishan Road, Shanghai, 200233, People’s Republic of China, Tel +8618964917372, Fax +8602164701361, Email fankunmazui@hotmail.com Xiao-Fang Yue, Department of Neurology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiaotong University, No. 600, Yishan Road, Shanghai, 200233, People’s Republic of China, Tel +8615821237895, Fax +8602164701361, Email klyxf@126.com
Background: Sufentanil-induced cough (SIC) frequently occurs during the induction of general anesthesia and may result in serious clinical complications, occasionally posing life-threatening risks. In clinical practice, we observed that oliceridine—a G protein-biased μ-opioid receptor agonist—demonstrates a potent suppressive effect on SIC. This study aimed to evaluate the efficacy of oliceridine in preventing SIC and to assess any associated adverse events.
Methods: In this prospective, randomized, double-blind, placebo-controlled trial, 286 adult patients undergoing elective surgery under general anesthesia were enrolled and randomly assigned to receive either 2 mg oliceridine (OS group) or an equal volume of normal saline (SS group) before intravenous administration of sufentanil. The primary outcome was the incidence of SIC. Secondary outcomes included the severity of cough, vital sign changes, and adverse events.
Results: The incidence of SIC was 42.66% in the SS group and 0% in the OS group (95% upper confidence bound ≈ 2.6%; P < 0.001). Among the SS group, mild, moderate, and severe cough occurred in 12.59%, 26.57%, and 3.50% of patients, respectively. No significant differences were observed in systolic or diastolic blood pressure, heart rate, or SpO2 between the two groups at baseline or 2 minutes post-sufentanil administration. The incidence of adverse events was low and comparable between groups, with no reported cases of apnea, nausea, or vomiting.
Conclusion: Pretreatment with 2 mg oliceridine demonstrated favorable effevtiveness in suppressing SIC without significant adverse effects. Oliceridine appears to be a safe and effective prophylactic strategy for preventing SIC and may have valuable clinical utility in anesthesia practice.
Keywords: oliceridine, sufentanil, opioid-induced cough, general anesthesia, μ-opioid receptor